Asha Balakrishnan
Overview
Explore the profile of Asha Balakrishnan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
39
Citations
1350
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Teuter M, Hu Y, Ross T, Lolatte K, Ott M, Bengel F, et al.
Nucl Med Biol
. 2025 Feb;
144-145:109000.
PMID: 39970776
Background: Hepatocellular carcinoma (HCC) is a leading cause of cancer-related deaths, globally. There is a need for novel biomarkers for early detection and novel, effective targeted therapies. Molecular imaging can...
2.
Zhong X, Ott M, Sharma A, Balakrishnan A
J Hepatol
. 2024 Oct;
82(3):414-416.
PMID: 39396645
No abstract available.
3.
Markovic J, Li R, Khanal R, Peng Q, Mobus S, Yuan Q, et al.
J Hepatol
. 2024 Sep;
82(2):301-314.
PMID: 39218230
Background & Aims: Liver fibrosis and its end-stage form cirrhosis contribute to millions of deaths annually. The lack of robust antifibrotic molecules is in part attributed to the absence of...
4.
Olarewaju O, Hu Y, Tsay H, Yuan Q, Eimterbaumer S, Xie Y, et al.
Cell Death Dis
. 2024 Jun;
15(6):456.
PMID: 38937450
Hepatocellular carcinoma is a primary liver cancer, characterised by diverse etiology, late diagnoses, and poor prognosis. Hepatocellular carcinoma is mostly resistant to current treatment options, therefore, identification of more effective...
5.
Bogomolova A, Balakrishnan A, Ott M, Sharma A
Cell Mol Gastroenterol Hepatol
. 2024 Jan;
17(4):607-622.
PMID: 38216053
Hepatic stellate cells (HSCs) and their activated derivatives, often referred to as myofibroblasts (MFs), play a key role in progression of chronic liver injuries leading to fibrosis, cirrhosis, and hepatocellular...
6.
Li R, Balakrishnan A, Ott M, Sharma A
Cell Stem Cell
. 2023 May;
30(5):504-506.
PMID: 37146576
In this issue, Wang et al. provide evidence of the pre-clinical as well as the clinical utility of in vitro-generated directly reprogrammed human hepatocytes in bioartificial liver. This approach will...
7.
Tsay H, Yuan Q, Balakrishnan A, Kaiser M, Mobus S, Kozdrowska E, et al.
J Hepatol
. 2022 Apr;
77(1):269.
PMID: 35397938
No abstract available.
8.
Yang T, Poenisch M, Khanal R, Hu Q, Dai Z, Li R, et al.
J Hepatol
. 2022 Apr;
77(1):270.
PMID: 35397937
No abstract available.
9.
Meumann N, Schmithals C, Elenschneider L, Hansen T, Balakrishnan A, Hu Q, et al.
Cancers (Basel)
. 2022 Jan;
14(2).
PMID: 35053588
Although therapeutic options are gradually improving, the overall prognosis for patients with hepatocellular carcinoma (HCC) is still poor. Gene therapy-based strategies are developed to complement the therapeutic armamentarium, both in...
10.
Yang T, Poenisch M, Khanal R, Hu Q, Dai Z, Li R, et al.
J Hepatol
. 2021 Aug;
75(6):1420-1433.
PMID: 34453962
Background & Aims: Therapeutic targeting of injuries that require transient restoration of proteins by mRNA delivery is an attractive approach that, until recently, has remained poorly explored. In this study,...